Loading this company
Loading this company
Priced within our range of ¥1,387.93 to ¥3,236.06.
¥2,759.50JPY up +¥19.00 (+0.69%)
Quoted · Prices are delayed.
Showing the last price we hold for this listing, recorded 2026-10-19 15:43 UTC (3 hours ago).
Nothing we can cite explains today’s move for this company.
Our range from 3 models, on today’s numbers
¥1,387.93–¥3,236.06
What the price needs: revenue growth of 15.0%/yr for 5 years (our model assumes 12.4%).
Led by discounted cash flow (DCF) · Dividend income business
Price ¥2,759.50Priced · Prices are delayed.
Our forward range over 12 months is part of Pro. See plans
Analysts’ mean target
¥4,027.50 across 16 analysts
The high and low of the analyst range is part of Pro. See plans
Daiichi Sankyo Company, Limited manufactures and sells pharmaceutical products in Japan and internationally. The company offers Enhertu for the treatment of HER2 positive and low breast cancer, HER2 positive gastric or gastroesophageal junction adenocarcinoma, and HER2 positive solid tumors; Turalio, an oral small molecule for colony stimulating factor 1 receptor, KIT proto-oncogene receptor tyrosine kinase, and FMS-like tyrosine kinase 3, as well as symptomatic TGCT; Vanflyta, a FLT3 inhibitor for the treatment of acute myeloid leukemia; Injectafer, a ferric carboxymaltose injection for the treatment of iron deficiency; and Datroway for the treatment of HR positive and HER2 negative breast cancer, as well as NSCLC. It operates in the Drug Manufacturers - General industry (Healthcare sector), headquartered in Japan. The company employs roughly 20,171 people.
Prices are delayed. The feed does not say when these figures were taken.
No filings or corporate activity on file in the recent window.
No recent headlines we can cite for this company.
No insider filings for this company in the recent window.
Not investment advice. TickerWorth Score is a model output.
The score, the fair value and the reverse DCF are free on every company. Pro lets you change growth, margin and the discount rate yourself, see every valuation lens and its working, and download the model. Start a 7-day free trial — a card is required and you can cancel any time before it ends. $99 a year, or $14.99 monthly.